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Residents of a community in Randolph
County, North Carolina, contacted the
Agency for Toxic Substances and Disease
Registry (ATSDR) because of health con-
cerns over possible exposures to chemical
emissions from a manufacturing plant in
their neighborhood. The facility produced
polyurethane foam by reacting a resin, typi-
cally a polyether such as polyoxypropylen-
etriol, with toluene diisocyanate (TDI) and
water. Small quantities of an emulsifying
agent, a polymerization catalyst, and a sili-
cone lubricant were also added. Emissions
from the foam-making process were direct-
ed to stacks, which vented them to ambient
air. Emissions from the process could also
escape from air vents in the building. Foam
production occurred in batches, which
resulted in episodic releases ofemissions.
Using a TDI tape meter, ATSDR staff
detected TDI in residential ambient air
near the facility at concentrations as high as
29 ppb (209 pg/m3). The presence ofTDI
in ambient air was confirmed by an alter-
nate method in which diisocyanates were
captured on glycerol-impregnated filters,
chemically derivitized, and analyzed using
high performance liquid chromatography.
TDI releases were episodic and usually
occurred every few days, although releases
were sometimes detected as often as twice a
day. During TDI releases, air levels were
typically elevated for less than 10 min.
However, on a few occasions, TDI levels
remained elevated for more than 1 hr.
Residents living near the plant expressed
concern over possible health effects from
breathingchemicals in air emissions from the
plant. TDI was ofparticular concern because
TDI can cause respiratory irritation and
asthma, which some residents had reported.
In response to these concerns, ATSDR, in
cooperation with the Randolph County
Health Department (RCHD), initiated an
exposure investigation. The purpose of this
investigation was to conduct biological mon-
itoring ofresidents to determine ifthey had
been exposed to TDI orotherdiisocyanates.
To measure occupational exposure to
TDI, researchers have measured levels of
toluene diamine (TDA) in hydrolyzed plas-
ma and urine (1). However, the half-life of
TDA in plasma is 6-10 days, so TDA bio-
monitoring can onlydetect recent exposure.
Other researchers have measured serum
antibodies to TDI and other diisocyanates
in occupationally exposed workers (2-5).
Biomonitoring for antibodies has the
advantage that antibodies can be detected
even though exposure has not recently
occurred. In TDI-sensitized workers, anti-
body titers decrease after exposure has
stopped, but antibodies can still be detect-
ed several months after total removal from
diisocyanate exposure (6).
In this investigation, blood samples
were obtained from the residents and tested
for antibodies to diisocyanates. The pres-
ence of antibodies to these chemicals was
used as a biomarker ofexposure. As defined
by the National Research Council, "A bio-
logical marker of exposure is a xenobiotic
chemical or its metabolite or the product of
an interaction between the chemical and
some target cell or biomolecule" (7).
Materials and Methods
The RCHD mailed flyers to residents to
inform them ofthe investigation. Residents
who lived within one-quarter mile of the
plant and those who were experiencing res-
piratory health problems were particularly
encouraged to participate. The minimum
age forparticipation was 2 years.
A total of 113 residents volunteered for
testing. This population consisted of 99
adults and 14 children (16 years of age or
younger). The gender distribution was 63
females and 50 males. This investigation
was conducted as a public health service, so
anyone who requested to be tested was
accepted; no attempt was made to select a
test population that paralleled the demo-
graphic makeup ofthe community.
Before testing, each adult participant
signed an informed consent form. Minors
and their parents or guardians signed an
assent form. A licensed medical technician
collected blood samples from 113 partici-
pants by venipuncture. The blood samples
were collected in 10-ml Vacutainer tubes.
At the end of the collection day, the tubes
were centrifuged and stored in a refrigerator
until they were shipped via overnight mail
on ice packs to the laboratory for analysis.
The blood specimens were sent to the
University of Cincinnati Diagnostic Allergy
Laboratory. The blood sera were analyzed by
an enzyme-linked immunosorbent assay
(ELISA) for IgG and IgE antibodies to TDI-
human serum albumin (HSA) conjugates,
hexamethylene diisocyanate (HDI-HSA), and
diphenylmethanediisocyanate (MDI-HSA).
IgG antibodies were assayed in triplicate
by coating microtiter plates with 100 pl of
an antigen solution, consisting of diiso-
cyanate-conjugated human serum albumin.
Plates were washed four times with phos-
phate-buffered saline (PBS)-0.5% Tween 20
(T-PBS) and blocked for 1 hr with 1% T-
PBS containing 1% bovine serum albumin
(BSA). After washing, 100 pl oftest sera was
diluted 1:10 and 1:100 in 5% BSAin T-PBS
and added to each test plate. Controls
included a positive reference serum and a
panel ofnormal sera obtained from laborato-
ry volunteers. After washing, goat anti-
human IgG conjugated to alkaline phos-
phatase and diluted in 1% BSA was added,
and the plates were incubated for 1 hr at
room temperature. After washing, 100 pl of
diluted substrate was added to each well. The
substrate consisted of a 1 mg/mI solution of
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p-nitrophenyl phosphate in substrate buffer
(10% diethanolamine containing 0.5 mM
MgCl2, pH 9.8). The plates were read at
410 nm usingan ELISAplate reader.
IgE antibodies were analyzed by a mod-
ification of the IgG protocol, substituting
ELISA reagents with specificity for the IgE
immunoglobulin isotype. Test sera were
diluted in 1% BSA instead of 5% BSA. In
addition, an extra step was added to the
IgG protocol; rabbit anti-goat IgG (H+L)
conjugated to alkaline phosphatase was
added after the goat anti-human IgE.
Results were analyzed by determining
the mean optical density (OD) ofthe three
replicate wells for each serum sample tested
at 1:10 and 1:100 dilutions. Samples were
classified as positive if they exceeded three
standard deviations above the mean OD of
seven negative control samples plus the
OD ofthe patient's human serum albumin
at the same serum dilution.
Results
Ofthe 113 participants that were tested, 10
people (9%) had antibodies to one or more
of the diisocyanates. Nine participants had
IgG antibodies to TDI, and one participant
had IgE antibodies to TDI. Four partici-
pants had antibodies that reacted with more
than one diisocyanate. The results of the
antibody tests are summarized inTable 1.
Individuals with positive antibody tests
were interviewed to identify possible sources
ofexposure to diisocyanates. One ofthe 10
positive individuals reported having occupa-
tional exposure to TDI or other diiso-
cyanates. In addition, two individuals report-
ed using polyurethane varnishes, a possible
source ofdiisocyanates, in their home. None
ofthe other seven positive individuals report-
ed exposure to polyurethane varnishes, con-
crete sealers, or otherknown sources ofdiiso-
cyanates (2,8).
Table 1. Participants with antibodies to diiso-
cyanates8
TDI HDI MDI
lb lgG(1:100) - IgE(1:100)
2 IgG --
3 IgG (1:100) lgG
IgE
4C lgG -
5 IgG -
6 IgG (1:100) -
7 IgG - IgG
8 IgG (1:100) - lgG
gc _ IgE -
10 IgG - -
Total 9 2 3
Abbreviations: TDI, toluene diisocyanate; HDI, hexameth-
ylene diisocyanate; MDI,diphenylmethane diisocyanate.
'The sera dilutions were 1:10 exceptwhere indicated.
bOccupational exposure.
cPossible exposure to diisocyanate-containing consumer products.
Discussion
Occupational exposure to TDI and other
diisocyanates can cause irritation of the
eyes, upper respiratory tract, and skin. It
has been estimated that 5-10% ofworkers
exposed to diisocyanates will develop occu-
pational asthma (2). In some instances,
exposure to TDI results in sensitization,
which is defined as a tendency to be sus-
ceptible to TDI at concentrations much
below those that affect most persons. The
exposure level ofTDI that causes sensitiza-
tion is not well characterized, but it can
occur at levels below the Occupational
Safety and Health Administration (OSHA)
short-term exposure level of20 ppb (9). In
one study, sensitization reportedly occurred
at exposure levels as low as 2 ppb (3).
It has been estimated that 10-30% of
symptomatic workers develop IgE antibodies
to diisocyanates (4. In one study of 1,780
workerswhowereexposed to diisocyanates in
the workplace, IgE antibodies to diiso-
cyanates were detected in 13.6% ofsympto-
maticworkers and in 8.4% ofallworkers (4).
Symptomatic workers were those who had
experienced bronchial asthma, chronic bron-
chitis, rhinitis, or conjunctivitis. In a repre-
sentative subgroup ofthis same population,
IgG antibodies were somewhat more preva-
lent, being detected in 24% ofsymptomatic
workers and 17% ofasymptomaticworkers.
There are few published data on the
incidence ofantibodies to diisocyanates in
the general public. In one study, none of
157 control subjects had IgG antibodies to
HDI (10). In another study, no IgE anti-
bodies to TDI, HDI, or MDI were detect-
ed in 40 unexposed referents from a blood
donor pool (11). These studies provide evi-
dence that antibodies to diisocyanates are
seldom detected in the general public.
In the present investigation, antibodies
to diisocyanates were detected in 9% ofthe
people living near the plant. This percent-
age is lower than what has been reported in
occupationally exposed populations.
However, this finding is not unexpected
because TDI exposures from residential air
were likely lower than TDI exposures from
an indoor occupational environment. Seven
of the positive individuals reported no
known exposure to diisocyanates. The pres-
ence ofTDI antibodies in these individuals
could have resulted from exposure to TDI
in ambient air near the facility.
Several of the participants had positive
antibody reactions to more than one diiso-
cyanate. Similar cross-reactivity of diiso-
cyanate antibodies has been previously
observed in occupationally exposed workers
(4,10). In one study, about 60% ofpositive
sera cross-reacted to varying degrees with one
or more diisocyanate-HSA conjugates (4).
Occupational exposure to TDI and
other diisocyanates can lead to asthma and
hypersensitivity pneumonitis (2,10).
However, the presence ofTDI antibodies
does not necessarily lead to clinical disease.
Occupational studies have demonstrated
that some workers have both antibodies to
TDI and exposure to TDI, yet they remain
asymptomatic. Conversely, occupational
asthma occurs in some TDI workers in the
absence ofTDI antibodies. Therefore, the
presence or absence ofTDI antibodies is a
poor predictor of clinical disease. In this
investigation, antibodies to diisocyanates
were used as a biomarker of exposure. No
attempt was made to correlate the presence
ofantibodies with respiratory disease.
Some ofthe participants in this investiga-
tion reported health problems that they
attributed to emissions from the plant.
Therefore, individuals who tested positive for
diisocyanate antibodies, as well as individuals
who were experiencing symptoms ofrespira-
tory disease, were encouraged to seek fiurther
clinical evaluation. The North Carolina
Department ofHealth and Human Services
made arrangements for qualified individuals
to receive further evaluation at a university
medical center.
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